Superworth

Polaryx Therapeutics PLYX

Drug Manufacturers - General, Healthcare
$1.85
−4.64%
Market cap
$92.2M
PE
n/m
one or more of the four quarters through 2026-06-30 missing
Forward PE
n/m
not a meaningful number
Price to sales
n/m
not a meaningful number
EV/EBIT
n/m
not a meaningful number
Revenue, 12 months
n/m
not a meaningful number
Net margin
n/m
not a meaningful number
Free cash flow yield
n/m
not a meaningful number

Charts

Financials

Income statement for PLYX, by quarter
Income statementQ1 FY25Q2 FY25Q1 FY26Q2 FY26
R&D$4.7M$476K$679K$719K
SG&A$336K$408K$1.3M$661K
−$5.1M−$884K−$2M−$1.4M
Net income−$5.1M−$1M−$2.5M−$1.4M
−$0.11−$0.02−$0.05−$0.03
44.3M44.7M47.2M48.3M

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest Polaryx Therapeutics' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
PLYXPolaryx Therapeutics$92.2Mn/mn/an/mn/mn/m
LFVNLifevantage$73.4M14.7×19.6×0.4×−20%2.8%
SPROSpero Therapeutics$64.6M10.1×9.5×1.4×−3%15.7%
ATNMActinium Pharmaceuticals$47.8M4.2×3.1×n/mn/mn/m
NATRNatures Sunshine Products$213.8M12.0×20.6×0.4×+7%3.7%
ARVNArvinas$477.3M45.6×52.3×1.5×−15%2.9%
PBYIPuma Biotechnology$568.9M21.2×12.3×2.5×−3%11.6%
IRWDIronwood Pharmaceuticals$571.7M4.5×14.9×1.5×+26%33.4%
ZVRAZevra Therapeutics$582.6M10.5×12.3×4.3×+119%42.8%
CRMDCorMedix$611.9M3.7×4.0×1.3×+281%40.5%
COLLCollegium Pharmaceutical$747.5M18.5×19.1×0.9×+14%5.9%
Peer median$523.1M11.3×13.6×1.4×+7%11.6%

More on Polaryx Therapeutics

Each number over time

Its groups

About

Industry
Drug Manufacturers - General
Sector
Healthcare

Valuation data, not investment advice. Prices as of .